ClearPoint Neuro repays $10M convertible note early, eliminates all debt

ClearPoint Neuro, Inc.

On Aug 23, 2024, fully repaid $10M convertible note held by PTC Therapeutics (orig. maturity Jan 2025).
Note was issued in Jan 2020; early repayment removes all debt from ClearPoint's balance sheet.
CEO says repayment avoids additional dilution and reflects confidence in the business.
PTC continues to support ClearPoint for Upstaza BLA submission to FDA for AADC deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.